

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
04 August 2022 (04.08.2022)



(10) International Publication Number
WO 2022/165027 A2

(51) International Patent Classification:
C12N 15/11 (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2022/014091

(22) International Filing Date:
27 January 2022 (27.01.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/142,121 27 January 2021 (27.01.2021) US
63/201,466 30 April 2021 (30.04.2021) US
63/261,603 24 September 2021 (24.09.2021) US

(71) Applicant: SPARK THERAPEUTICS, INC. [US/US];
3737 Market Street, Ste. 1300, Philadelphia, PA 19104
(US).

(72) Inventors: RILING, Christopher; 702 N. Whitford Road,
Exton, PA 19341 (US). PANKOWICZ, Francis; 4700
Kingsessing Avenue, Philadelphia, PA 19143 (US). AR-
MOUR, Sean; 16 Thoroughbred Drive, Holland, PA 18966
(US). QUINN, William John, III; 508 S. 46th Street,
Philadelphia, PA 19143 (US). PRESTON, Michael; 20
Blakely Road, Downingtown, PA 19335 (US). IOELE,
Stephen; 44 Colts Gait Road, Marlton, NJ 08053 (US).
COHEN, Daniel; 502 Governors Court, Philadelphia, PA
19146 (US). SEE, Zhenwei Kelvin; 115 Eaton Drive,
Wayne, PA 19087 (US).

(74) Agent: HEBER, Sheldon Orly et al.; ICE MILLER
LLP, 1735 Market Street, Suite 3900, Philadelphia, PA
19103-7509 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

Declarations under Rule 4.17:

- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- without international search report and to be republished
upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

WO 2022/165027 A2

(54) Title: COMPOSITIONS AND METHODS FOR TREATING HEREDITARY ANGIOEDEMA

(57) Abstract: Nucleic acids encoding C1 inhibitor are described. Also described are expression cassettes, vectors, cells, and cell lines containing the nucleic acids, as well as methods of using the nucleic acids to treat complement-mediated disorders, such as hereditary angioedema.